Fighting against hematological malignancy in China: from unique system to global impact

作     者：LV Meng HUANG XiaoJun 

作者机构：Peking University People's Hospital Peking University Institute of Hematology Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Peking-Tsinghua Center for Life Sciences 

出 版 物：《Science China(Life Sciences)》 (中国科学（生命科学英文版）)

年 卷 期：2015年第58卷第12期

页      面：1183-1190页

核心收录：

学科分类：0710[理学-生物学] 0830[工学-环境科学与工程（可授工学、理学、农学学位）] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Natural Science Foundation of China(81230013 81400146 81530046) the Beijing Municipal Science and Technology Program(Z141100000214011) 

主　　题：hematological malignancy acute promyelocytic leukemia acute myeloid leukemia chronic myeloid leukemia haploidentical hematopoietic stem cell transplantation 

摘      要：During recent decades, substantial progress has been made in clinical strategies for treating hematological malignancies. Not only did China benefit from the global progression in the management of acute promyelocytic leukemia, risk-stratification-directed strategies for acute or chronic leukemia and haploidentical hematopoietic stem cell transplantation, the unique system developed by Chinese doctors has also become inspiration for refining global clinical practice. The multicenter trials and collaborations adhering to international standards might further strengthen the global impact and lead the way in specific fields of research worldwide.